TRUE-1: Trial of Repurposed Unithiol for snakebite Envenoming phase 1 (safety, tolerability, pharmacokinetics and pharmacodynamics in healthy Kenyan adults)

Background: Snakebites affect over 5 million people each year, and over 100,000 per year die as a result. The only available treatment is antivenom, which has many shortcomings including high cost, intravenous administration, and high risk of adverse events. One of the most abundant and harmful comp...

Descripción completa

Detalles Bibliográficos
Autores principales: Abouyannis, Michael, FitzGerald, Richard, Ngama, Mwanajuma, Mwangudzah, Hope, Nyambura, Yvonne K., Ngome, Samson, Riako, Debra, Babu, Lawrence, Lewa, Frida, Else, Laura, Dily Penchala, Sujan, Orindi, Benedict, Mumba, Noni, Kalama, Betty, Ndungu, Francis M., Adetifa, Ifedayo, Khoo, Saye, Lalloo, David G., Casewell, Nicholas R., Hamaluba, Mainga
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000 Research Limited 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8961198/
https://www.ncbi.nlm.nih.gov/pubmed/35372700
http://dx.doi.org/10.12688/wellcomeopenres.17682.1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8961198/
https://www.ncbi.nlm.nih.gov/pubmed/35372700
http://dx.doi.org/10.12688/wellcomeopenres.17682.1

Ejemplares similares